MI-2-2 is a potent menin-MLL inhibitor. MI-2-2 binds to menin with low nanomolar affinity (K d =22nM) and very effectively disrupts the bivalent protein-protein interaction between menin and MLL. MI-2-2 has specific and very pronounced activity in MLL leukemia cells, including inhibition of cell proliferation, down-regulation of Hoxa9 expression, and differentiation. In Vitro MI-2-2 is capable of inhibiting both the interaction of menin with MBM1 (IC 50 = 46 nM) and with the bivalent fragment of MLL that comprises both MBM1 and MBM2 (IC 50 =520 nM). MI-2-2 exhibits very pronounced activities at low micromolar concentrations in BMCs transformed with MLL-AF9 and in MV4;11, a human leukemia cell line harboring the MLL-AF4 translocation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid